Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | 6 | 4CA18C1 | OT / LA |
administration of DAPTACEL instead of TDaP to an 11-year-old patient with no reported adverse event; administration of DAPTACEL instead of TDaP to an 11-year-old patient with no reported adverse event; Initial information received on 30-Jan-2026 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 11 years old female patient who had administration of Diphtheria-15/Tetanus/5 Ac Pertussis Vaccine [Daptacel] instead of Diphtheria, Tetanus And Acellular Pertussis Vaccine [tdap] with no reported adverse event. The patient's past vaccination(s) included Pediarix. The patient's past medical history, medical treatment(s) and family history were not provided. Concomitant medications included Meningococcal vaccine A/C/Y/W conj (tet tox) (Menquadfi) for Immunisation. On 27-Jan-2026, the patient at 11 years of age accidentally received a dose 6 with 0.5 ml Once dosage of suspect Diphtheria-15/Tetanus/5 Ac Pertussis Vaccine Suspension for injection (lot 4CA18C1, Expiry: 28-feb-2027, strength: standard) via intramuscular route in the left arm as immunization instead of Diphtheria, Tetanus And Acellular Pertussis Vaccine [tdap] produced by unknown manufacturer with no reported adverse event (wrong product administered) (product administered to patient of inappropriate age) (Latency: same day). It was reported, "She asked if there are side effects, see if an extra TDaP dose should be given, or what should they do." Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Menquadfi